Humana Inc. priced a $1 billion public offering of junior subordinated notes due 2056 at 100.0 percent of the principal amount, with the transaction expected to close on March 9 2026. The notes are fixed‑to‑fixed rate, and the net proceeds are projected to be approximately $986 million.
The company will use the proceeds for general corporate purposes, including the refinancing of commercial‑paper borrowings that financed its recent acquisition of MaxHealth, a Florida‑based primary‑care network. The refinancing is intended to optimize Humana’s capital structure after the acquisition and to provide additional working‑capital flexibility.
AM Best assigned the notes a long‑term issue credit rating of “bbb‑” (Good) with a stable outlook, confirming the credit quality of the new debt. The notes mature in 2056, and the pricing at 100 percent of principal reflects the market’s confidence in Humana’s credit profile.
The issuance will increase Humana’s financial leverage to roughly 41.8 percent of capital, slightly above the company’s long‑term target of 40 percent. S&P Global Ratings notes that leverage is expected to peak at 42.5‑44.5 percent in 2026 before falling toward the target in 2027. Management plans to manage leverage through equity increases and deleveraging initiatives.
In a February 11 earnings release, President and CEO Jim Rechtin said, “We were pleased with our solid financial performance and operational progress in 2025. We continue to feel good about our consumer‑focused strategy and our individual Medicare Advantage membership growth in 2026, which will allow us to build for the future with even better outcomes and experiences.” The company faces headwinds from declining Medicare Advantage Star Ratings, which have pressured quality‑bonus payments and reduced operating results, but the new debt provides a buffer as Humana navigates these challenges.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.